CION Ameerpet
CAR-T & Cell Therapy — Paying For It
Funding CAR-T — Insurance, Schemes and Assistance
A CAR-T course in India runs into tens of lakhs, and almost no standard Indian policy covers it in full. Some insurance cover exists, a handful of schemes and relief funds apply, and most families end up combining four or five routes. CION Cancer Clinics does not provide or fund CAR-T — this page is orientation and referral guidance only. Figures indicative, as of August 2026.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Is it covered? — some private policies now consider CAR-T, but cover is policy-specific, usually capped well below the bill, and needs written pre-authorisation
- Which schemes apply? — PM-JAY, Aarogyasri, CGHS, ECHS, ESI and the national and state relief funds — what each one realistically does, and what it does not
- What assistance exists? — hospital charitable trusts, disease foundations, employer CSR, crowdfunding and clinical trials — with honest timelines for each
- What CION can do for you — read your reports free of charge, say plainly whether CAR-T is even in the conversation, and refer you on when it is
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Short Answer
Is CAR-T cell therapy covered by insurance in India?
Partly, and almost never in full. A growing number of Indian private health policies now consider CAR-T cell therapy, but cover is policy-specific, usually capped well below the total bill, and always needs written pre-authorisation. Government package schemes generally do not list it. Most families fund the gap from several sources at once.
Why the cap, not the price, is the real problem. The cell product alone has been reported in the region of ₹30 lakh to ₹45 lakh for the therapy manufactured in India, indicative, as of August 2026. Eligibility testing, cell collection, conditioning chemotherapy, two to four weeks of monitoring and the treatment of any reaction are billed on top of it. A typical Indian family floater is a fraction of that figure. Even a large sum insured can be cut down by sub-limits, room-rent caps and a waiting period on pre-existing disease.
What to read in your policy, in this order. First, the exclusions clause — if gene therapy, cell therapy or “experimental and investigational treatment” appears there, that one line decides the claim. Second, the sub-limit that actually applies to this treatment, not the headline sum insured on the cover page. Third, the pre-existing-disease waiting period. Fourth, whether the accredited centre is inside your insurer’s network, because outside it you are on reimbursement rather than cashless, and reimbursement means your family pays first.
Nothing verbal counts. Ask the insurer for written pre-authorisation against the centre’s itemised estimate before any date is booked. A helpline assurance, an agent’s message and a counsellor’s opinion are all worth nothing at discharge. If the insurer declines, ask for the refusal in writing with the clause cited — that letter is the first document a trust or a relief fund will ask you for.
Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy. We do not administer it, stock it, manufacture it or fund it, and we quote no price for it. This page maps the funding routes that exist so you can plan, and so we can point you to an accredited centre if your diagnosis is one where CAR-T is genuinely on the table.
Did you know?
For most families the binding constraint is not the sticker price but the funding calendar. Insurance pre-authorisation, trust applications and crowdfunding each take weeks, and they run while relapsed disease is still moving. Families who open every funding channel on the day of referral, rather than after eligibility is confirmed, get to a decision far sooner. Timelines indicative, as of August 2026.
Every Route That Exists
Which schemes and funding routes actually apply to CAR-T?
About eleven routes exist in practice. Private insurance, corporate group cover and employer CSR. Ayushman Bharat PM-JAY and state schemes such as Aarogyasri. CGHS, ECHS and ESI. The Health Minister’s Cancer Patient Fund and the national and state relief funds. Hospital trusts. Crowdfunding. A clinical trial, where one is open.
| Funding route | Who it applies to | What it realistically does | Typical time to a decision |
|---|---|---|---|
| Private health insurance | Anyone with an in-force individual or family floater policy | May cover part of the hospitalisation. Cover is policy-specific and commonly capped far below the total. Written pre-authorisation is essential | 1–4 weeks |
| Corporate or group medical cover | Salaried employees and their dependants | Often carries a limit separate from the personal policy, and sometimes a top-up on it. Ask HR for the written policy limit, not the headline sum insured | 1–3 weeks |
| Employer CSR or staff welfare fund | Employees of larger organisations and PSUs | A discretionary grant towards treatment. The centre’s itemised estimate has to be attached to the application | 2–8 weeks |
| Ayushman Bharat PM-JAY | Families holding a PM-JAY entitlement | Works from a defined package list at empanelled hospitals. Cell therapy has not been a routine listed package — verify the current list before planning around it | Verify first |
| Aarogyasri and comparable state schemes | Eligible ration-card holders in Telangana, Andhra Pradesh and other states | Listed procedure packages with published ceilings at empanelled hospitals. Cell therapy has not been a routine listed package — ask for the current entry in writing | Verify first |
| CGHS, ECHS, ESI, railway and PSU schemes | Government, defence, railway and PSU staff and pensioners | Referral-based cover or reimbursement at approved rates. High-cost items are escalated for sanction, so start early and keep the referral chain complete | 3–10 weeks |
| Health Minister’s Cancer Patient Fund / Rashtriya Arogya Nidhi | Poor patients treated at approved institutions | A grant paid towards treatment at the treating institution. Applied for through that institution, with the estimate and income proof | 4–12 weeks |
| PM National Relief Fund and Chief Minister’s Relief Fund | Means-tested applicants; state rules vary | A one-off grant, usually a part contribution rather than the whole cost. Submitted through the treating hospital with the estimate attached | 4–12 weeks |
| Hospital-linked charitable trusts and disease foundations | Patients accepted at that centre, means-tested | Assist selected patients with part of the product or hospital cost. The centre’s medical social worker is the person to ask | 2–8 weeks |
| Crowdfunding platforms | Anyone, subject to platform verification | Whatever is actually raised. No ceiling, and no certainty. Needs time and a verified medical record to gain momentum | 3–8 weeks to mature |
| A clinical trial, where one is open | Patients meeting that trial’s strict criteria | May cover the investigational product itself. Enrolment is never certain and no trial should be presented to you as a sure thing | Depends on the trial |
Read the table as a map, not a promise. None of these routes is a CION rate, offer or arrangement, and no CAR-T product is named anywhere on this page. What any one family receives depends on the policy wording, the scheme list current on the day, the treating institution and the documents submitted. Ask the centre’s counsellor to confirm each route in writing before you build a plan on it.
Beyond The Policy
What assistance exists if insurance says no?
A refusal letter is not the end of the process. It is the document the next five routes ask to see. Charitable assistance, relief funds, employer schemes, crowdfunding and trials all sit outside insurance, and families usually run them in parallel rather than one after another.
- The centre’s medical social worker — the single most useful person in this process. They know which trusts are currently funding, what each one asks for, and how long that centre’s applications are taking. Ask for them by name at the first appointment.
- Hospital-linked trusts and disease foundations — they assist selected patients with part of the cost and need the itemised estimate, the diagnostic record and income proof. Applications are made through the treating institution, not directly by the family.
- Government relief funds — the Health Minister’s Cancer Patient Fund, the Prime Minister’s National Relief Fund and your state’s Chief Minister’s Relief Fund. All are means-tested, all go through the hospital, and all take weeks.
- Crowdfunding, started early — widely used in India and genuinely effective for some families. It takes weeks to build, so it belongs at the start of the plan and not after everything else has failed. Keep the medical record accurate; platforms verify it.
- A clinical trial, where one is open and you qualify — a trial may cover the investigational product. Criteria are strict, slots are limited, and enrolment is never certain. Trials are informational here; nothing on this page is a recruitment offer.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Funding is the slowest step. Start it the day you are referred.
CION does not provide or fund CAR-T cell therapy. We do read your reports, explain what is realistic for your diagnosis, and point you to an accredited centre when that is the right next step.
Day One To Decision
How do you actually build the funding, step by step?
Five steps, all started in the same week. The order below is about what unlocks what: nothing moves until you hold an itemised written estimate, and every other application asks for that document. Our companion page on what CAR-T cell therapy costs in India breaks that estimate down line by line.
-
Get the itemised written estimate
Ask the accredited centre for an estimate split into the cell product, eligibility workup, collection, conditioning chemotherapy, hospital stay, monitoring and reaction treatment, with exclusions stated. Every insurer, trust and relief fund asks for this document. Without it, no application can even be filed.
-
Read the policy wording and file for pre-authorisation
Read the exclusions, the sub-limit and the waiting period in the policy document itself, not the brochure. Then file for written pre-authorisation against the estimate. If it is declined, ask for the refusal letter with the clause cited, because the next five applications will want to see it.
-
Open the employer and scheme channels the same week
Ask HR for the group cover limit and whether a CSR or welfare fund exists. In parallel, ask the centre’s scheme counsellor to check your PM-JAY, Aarogyasri, CGHS, ECHS or ESI entitlement against the current package list, and to put the answer in writing. These run independently of the insurance claim.
-
Apply to trusts and relief funds through the hospital
The medical social worker files these, not the family. Hand over one clean bundle: estimate, full diagnostic record, the treating haemato-oncologist’s recommendation letter, identity and income proof, and any refusal letter. Four to twelve weeks is normal, so this cannot wait until the other routes have failed.
-
Start crowdfunding early and budget for the overrun
Campaigns take weeks to build, so start while the other applications are pending. Budget beyond the estimate too: weeks of family accommodation near the centre, lost income, bridging treatment during the manufacturing wait, and the cost of treating a reaction if one occurs. Ask the centre what happens if a batch fails release testing, and who pays for the repeat.
Avoidable Refusals
Why do CAR-T funding applications get refused?
Most refusals are paperwork, not principle. Five patterns account for the majority of them, and every one is avoidable if you know about it on day one rather than at week six.
- An exclusion nobody read — gene therapy, cell therapy or “experimental and investigational treatment” sitting in the policy exclusions. Read that clause before you build any plan around the policy, and get the insurer’s position in writing.
- A verbal assurance instead of a written pre-authorisation — helpline confirmations and agents’ messages do not bind an insurer at discharge. Only a written pre-authorisation issued against the itemised estimate does.
- An incomplete estimate — one that shows a single total, with no split between product, stay, monitoring and reaction treatment, and no exclusions stated. Trusts and relief funds routinely return these unprocessed.
- Applications started in sequence — waiting for the insurer to answer before approaching trusts adds weeks the disease does not always allow. Run every channel in parallel from the day of referral.
- Missing records — a marrow report, an immunophenotyping result or a prior treatment summary that nobody can find. Assemble one complete set early, keep a scanned copy, and reuse it for every application.
Where CION Fits
Does CION provide or fund CAR-T cell therapy?
No. CION Cancer Clinics does not administer, stock, manufacture or fund CAR-T cell therapy or any other cell therapy, and quotes no price for it. If a page, an agent or a forwarded message tells you otherwise, it is wrong.
What we do is read your reports and give you a straight answer: whether your diagnosis is even in a category where CAR-T gets discussed, what the funding pathway would realistically demand of your family, and what the treatment you have already been offered is worth as a written second opinion. Where referral to an accredited cell-therapy centre is the right next step, we say so, and we help you prepare the record that every application will ask for.
The immunotherapy given as day care at CION Cancer Clinics is checkpoint-inhibitor treatment — a different class of treatment, with a different mechanism, schedule, cost profile and side-effect pattern. Response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION. Our first consultation is free, takes 45 minutes, and carries no commitment to start treatment anywhere.
You are not alone
Most families reach this page weighing an impossible number against hope
Ask us what your diagnosis actually calls for. You will get a plain answer, including when the answer is that CAR-T is not relevant to your case.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Funding CAR-T therapy in India: your questions answered
Is CAR-T cell therapy covered by insurance in India?
Partly, and almost never in full. A growing number of Indian private health policies now consider CAR-T cell therapy, but cover is policy-specific, usually capped well below the total bill, and always needs written pre-authorisation. Read the exclusions clause first: if gene therapy, cell therapy or experimental and investigational treatment is excluded, that single line decides the claim. Then read the sub-limit that applies, not the headline sum insured, and the waiting period on pre-existing disease. Ask the insurer to pre-authorise in writing against the centre's itemised estimate before any date is booked, and if the answer is no, ask for the refusal letter with the clause cited.
Does Ayushman Bharat or Aarogyasri cover CAR-T cell therapy?
Both schemes work from a defined package list at empanelled hospitals, and cell therapy has not been a routine listed package. Treat that as the position to verify rather than a settled fact, because package lists and ceilings are revised periodically. Ask the treating centre's scheme counsellor to check the current list against your card, in writing, before you plan around it. Where no package exists, families are usually redirected to the relief funds and hospital trusts instead. Scheme ceilings are published as text by the scheme itself, so ask for the current entry rather than a forwarded screenshot. Indicative, as of August 2026.
Which schemes and funds can a family in India apply to?
In practice there are about eleven routes. Private health insurance, corporate group cover and employer CSR or staff welfare funds. Ayushman Bharat PM-JAY and state schemes such as Aarogyasri. Service schemes including CGHS, ECHS, ESI and railway or PSU medical schemes. The Health Minister's Cancer Patient Fund and Rashtriya Arogya Nidhi. The Prime Minister's National Relief Fund and your state's Chief Minister's Relief Fund. Hospital-linked charitable trusts and disease foundations. Crowdfunding. And a clinical trial, where one is open and you meet the criteria. Very few of these cover the whole cost, so almost every family combines four or five.
How long does it take to arrange funding for CAR-T therapy?
Plan for weeks, not days. Insurance pre-authorisation commonly takes one to four weeks. Employer and group channels take one to three weeks through HR. Relief funds and charitable trusts routinely take four to twelve weeks, because they are processed through the treating institution. Crowdfunding takes three to eight weeks to mature. Funding is usually the single longest step between referral and infusion, and it runs while relapsed disease is still moving, which is why centres give bridging treatment during the wait. Open every channel on the day you are referred rather than after eligibility is confirmed. Timelines indicative, as of August 2026.
What documents will an insurer or a trust ask for?
Broadly the same bundle each time. The treating centre's itemised written estimate, split into product, hospital stay, monitoring and reaction treatment, with exclusions stated. The full diagnostic record, including biopsy or marrow reports, immunophenotyping, imaging and every line of treatment already given. A letter from the treating haemato-oncologist explaining why CAR-T is being recommended now. Your policy document or scheme card, plus identity and income proof for means-tested funds. Any refusal letter you have already received. Assemble one clean set early and reuse it, because chasing a missing report is the commonest reason an application stalls.
Does CION Cancer Clinics provide or fund CAR-T therapy?
No. CION Cancer Clinics does not administer, stock, manufacture or fund CAR-T cell therapy or any other cell therapy, and quotes no price for it. This page is orientation and referral guidance only. What CION can do is read your reports free of charge, tell you plainly whether your diagnosis sits in a category where CAR-T is genuinely discussed, explain what the funding pathway would demand of your family, and give a written second opinion on the treatment already offered. Where referral to an accredited cell-therapy centre is the right next step, we will say so and help you prepare the record.